Research activities of the Nuclear Medicine Unit focus on radionuclide therapy and molecular imaging SPET/CT and PET/CT in different tumors (thyroid, head and neck, sarcoma, gynecological and urological tumors, lymphoma, breast and lung cancer, liver tumors) aiming to improve early diagnosis, biological characterization and response monitoring, biological volume contouring to guide radiotherapy.

Main currently specific topic of research includes:

  • New PET radiopharmaceuticals (64-Cu and 64 Cu-PSMA) performance and safety evaluation in prostate cancer
  • F-choline diagnostic performance in early prostate cancer recurrence detection at low PSA values
  • Clinical impact of SPET/CT vs. to standard planar or SPET protocols in oncology
  • Comparison of clinical impact and cost-effectiveness of different available diagnostic technologies of bone imaging (bone scintigraphy vs. F-choline PET)
  • Role of FDG PET in clinical management of musculoskeletal tumors
  • Biodistribution, radiobiological effects and long –term safety studies after treatment with alfa –emitter (223-radium) in metastatic prostate cancer patients and adapted protocols
  • Role of integrated imaging with 131I SPET/CT and 18F-FDG PET/CT in advanced thyroid carcinoma both for diagnosis than for biological and dosimetric optimization
  • Identification of specific selective internal radiation therapy with 90Y- and 166 Ho -microspheres indications in the context of the standard HCC guidelines
  • Quantitative 3D dosimetry based on hybrid imaging and biomarkers correlation to optimize therapy in HCC patients treated with 90Y and 166-HO microspheres and in NET tumors treated with 177- Lu - Oxodotreotide.